A detailed history of Credit Suisse Ag transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 11,603 shares of MDGL stock, worth $2.52 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,603
Previous 10,528 10.21%
Holding current value
$2.52 Million
Previous $2.44 Million 27.23%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$171.37 - $283.23 $184,222 - $304,472
1,075 Added 10.21%
11,603 $3.1 Million
Q4 2023

Feb 08, 2024

SELL
$120.4 - $237.13 $20,708 - $40,786
-172 Reduced 1.61%
10,528 $2.44 Million
Q3 2023

Nov 13, 2023

SELL
$146.04 - $225.78 $489,087 - $756,137
-3,349 Reduced 23.84%
10,700 $1.56 Million
Q2 2023

Aug 11, 2023

BUY
$203.88 - $312.0 $725,608 - $1.11 Million
3,559 Added 33.93%
14,049 $3.25 Million
Q1 2023

May 10, 2023

BUY
$231.06 - $307.08 $111,833 - $148,626
484 Added 4.84%
10,490 $2.54 Million
Q4 2022

Feb 13, 2023

SELL
$58.39 - $296.54 $3,620 - $18,385
-62 Reduced 0.62%
10,006 $2.9 Million
Q3 2022

Nov 10, 2022

BUY
$60.57 - $79.51 $96,609 - $126,818
1,595 Added 18.82%
10,068 $655,000
Q2 2022

Aug 12, 2022

BUY
$58.04 - $100.2 $16,193 - $27,955
279 Added 3.4%
8,473 $606,000
Q1 2022

May 16, 2022

BUY
$55.89 - $101.89 $86,126 - $157,012
1,541 Added 23.16%
8,194 $804,000
Q4 2021

Feb 14, 2022

SELL
$72.34 - $95.09 $76,608 - $100,700
-1,059 Reduced 13.73%
6,653 $564,000
Q3 2021

Nov 12, 2021

BUY
$78.35 - $105.02 $121,129 - $162,360
1,546 Added 25.07%
7,712 $615,000
Q2 2021

Aug 16, 2021

SELL
$97.2 - $137.59 $277,603 - $392,957
-2,856 Reduced 31.66%
6,166 $601,000
Q1 2021

May 14, 2021

SELL
$108.54 - $125.2 $647,983 - $747,444
-5,970 Reduced 39.82%
9,022 $1.06 Million
Q4 2020

Feb 12, 2021

BUY
$110.06 - $133.7 $521,574 - $633,604
4,739 Added 46.22%
14,992 $1.67 Million
Q3 2020

Nov 13, 2020

SELL
$99.78 - $124.21 $1.2 Million - $1.5 Million
-12,043 Reduced 54.01%
10,253 $1.22 Million
Q2 2020

Aug 12, 2020

BUY
$60.13 - $125.71 $562,997 - $1.18 Million
9,363 Added 72.4%
22,296 $2.53 Million
Q1 2020

May 13, 2020

SELL
$66.76 - $93.49 $591,827 - $828,788
-8,865 Reduced 40.67%
12,933 $863,000
Q4 2019

Feb 12, 2020

BUY
$84.28 - $118.5 $1.12 Million - $1.58 Million
13,335 Added 157.57%
21,798 $1.99 Million
Q3 2019

Nov 12, 2019

BUY
$84.4 - $106.53 $160,950 - $203,152
1,907 Added 29.09%
8,463 $729,000
Q2 2019

Aug 14, 2019

SELL
$91.13 - $142.5 $37,363 - $58,425
-410 Reduced 5.89%
6,556 $687,000
Q1 2019

May 14, 2019

SELL
$103.48 - $143.84 $12,728 - $17,692
-123 Reduced 1.74%
6,966 $871,000
Q4 2018

Feb 13, 2019

BUY
$94.77 - $215.54 $127,844 - $290,763
1,349 Added 23.5%
7,089 $799,000
Q3 2018

Nov 13, 2018

SELL
$207.3 - $300.31 $631,850 - $915,344
-3,048 Reduced 34.68%
5,740 $1.23 Million
Q2 2018

Aug 14, 2018

BUY
$101.55 - $313.9 $304,142 - $940,130
2,995 Added 51.7%
8,788 $2.46 Million
Q1 2018

May 15, 2018

BUY
$93.35 - $149.04 $70,665 - $112,823
757 Added 15.03%
5,793 $677,000
Q4 2017

Feb 14, 2018

BUY
$39.35 - $97.37 $198,166 - $490,355
5,036
5,036 $462,000

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $3.71B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Credit Suisse Ag Portfolio

Follow Credit Suisse Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.